| Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. | |
| | |
MedLine Citation:
|
PMID: 15957544 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients with end-stage renal disease (ESKD) present an immunodeficiency state paradoxically exacerbated by hemodialysis (HD) and associated with signs of T-cell activation. B cells are also activated in uremia, and this activation could be altered by erythropoietin therapy in HD patients. In this study, the effects of human recombinant erythropoietin (rHu-EPO) and 1-alpha-D3 treatments on lymphocyte immunomodulatory enzymes, aminopeptidase N (APN), and 5'-nucleotidase activity in patients on HD were investigated in hemodialysis patients before and after two-month treatment with s.c. rHu-EPO (15 patients, 2000-3000 U three times weekly) or oral 1-alpha-D3 (14 patients, 2 microg three times weekly). RESULTS: A two-month EPO treatment of 15 HD patients produced a rise in hemoglobin from 6.51 +/- 0.18 to 9.69 +/- 0.14 g/dL. Basal lymphocyte APN activity in HD patients was not significantly different from the level in healthy controls. Treatment of patients with rHu-EPO increased unstimulated lymphocyte APN activity to values significantly higher than those before treatment (p<0.05). A two-month pulse oral 1-alpha-D3 treatment of 14 HD patients increased hematocrit by 21% and raised hemoglobin from 7.11 +/- 0.32 to 8.80 +/- 0.39 g/dL. Unstimulated and Con A-stimulated lymphocyte APN activity after pulse oral 1-alpha-D3 was significantly increased (p<0.01 and p<0.05, respectively) from the pretreatment levels. In HD patients lymphocyte basal, Con A-, and PMA-stimulated 5'-nucleotidase activity was significantly higher (p<0.05) than it was in healthy controls. The two-month treatment with rHu-EPO or pulse oral 1-alpha D3 did not change the level of lymphocyte 5'-nucleotidase in these patients. CONCLUSIONS: This study demonstrated that a two-month treatment of HD patients with rHu-EPO or pulse oral 1-alpha D3 significantly increases activity of lymphocyte APN, important for cleavage of peptides and small proteins, which accumulate in the blood of ESKD patients. In HD patients lymphocyte ecto-5'-nucleotidase activity was significantly higher than that in healthy controls and was not changed after a two-month treatment with rHu-EPO or pulse oral 1-alpha D3. We speculate that oxidative stress activates 5'-nucleotidase and production of adenosine by lymphocytes of HD patients. |
| | |
Authors:
|
Vladisav Stefanovic; Marina Mitić-Zlatkovic; Jasmina Radivojevic; Predrag Vlahovic |
Related Documents
:
|
16311264 - Haemodialysis vascular access problems in canada: results from the dialysis outcomes an... 8728214 - A comparison of bone scans in uremic patients treated with intermittent peritoneal dial... 19602614 - Oral health and inflammation in patients with end-stage renal failure. 19293594 - Physical activity, high-density lipoprotein cholesterol subfractions and lecithin:chole... 22249874 - Controlled study of the frequency of anti-hsp 70 with the elisa and the western blot me... 18209134 - Muc2 expression in human middle ear epithelium of patients with otitis media. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Renal failure Volume: 27 ISSN: 0886-022X ISO Abbreviation: Ren Fail Publication Date: 2005 |
Date Detail:
|
Created Date: 2005-06-16 Completed Date: 2005-09-22 Revised Date: 2008-05-21 |
Medline Journal Info:
|
Nlm Unique ID: 8701128 Medline TA: Ren Fail Country: United States |
Other Details:
|
Languages: eng Pagination: 283-8 Citation Subset: IM |
Affiliation:
|
Institute of Nephrology and Hemodialysis, Faculty of Medicine, Nis, Serbia. stefan@ni.ac.yu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
5'-Nucleotidase
/
metabolism* Administration, Oral Adult Aged Anemia / blood, drug therapy*, etiology Antigens, CD13 / metabolism* Biological Markers / metabolism Cells, Cultured Drug Therapy, Combination Erythropoietin, Recombinant / administration & dosage, therapeutic use* Female Follow-Up Studies Hemoglobins / metabolism Humans Kidney Failure, Chronic / blood*, complications, therapy Lymphocytes / cytology, enzymology* Male Middle Aged Treatment Outcome Vitamin D / administration & dosage, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Erythropoietin, Recombinant; 0/Hemoglobins; 1406-16-2/Vitamin D; 78609-64-0/1-alpha, 25-difluorovitamin D3; EC 3.1.3.5/5'-Nucleotidase; EC 3.4.11.2/Antigens, CD13 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients under...
Next Document: Prediction of mortality in acute renal failure in the tropics.